Ipsen warns over medicine supplies amid Brexit uncertainty

France’s Ipsen has become the latest pharma company to warn about the impact of Brexit on the pharma industry and patients’ access to medicines.

AZ begins liver cancer immunotherapy tie-up with AVEO

AstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in liver cancer.

Merck gets FDA okay for Keytruda as liver cancer therapy

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ri

EU regulators back Ipsen cancer drug in new liver cancer use

Ipsen’s bid to build a cancer franchise around its Cabometyx (cabozantinib) is gathering pace after European regulators backed it in a new indication of second line liver cancer – a use whe

Eisai/Merck & Co's Lenvima approved in EU for first line liv...

The European Commission has approved Eisai/Merck & Co's Lenvima as a new first-line treatment for liver cancer.

Eisai’s EMEA CEO Gary Hendler on why quality of life is key ...